Bimekizumab and progressive pulmonary fibrosis in severe psoriasis: a case report
Abstract
Psoriasis is a chronic immune-mediated inflammatory disease frequently associated with systemic comorbidities, including an increased prevalence of interstitial lung diseases (ILDs). Progressive fibrosing ILDs are characterized by declining respiratory function and high morbidity, and emerging evidence suggests that type-17 immune pathways may contribute to both psoriatic inflammation and pulmonary fibrosis. Bimekizumab, a monoclonal antibody selectively targeting IL-17A and IL-17F, has demonstrated high efficacy in psoriasis, although its potential impact on fibrotic lung disease remains unclear. We report the case of a 58-year-old man with severe plaque psoriasis and concomitant desquamative interstitial pneumonia (DIP) with features of progressive pulmonary fibrosis. The patient presented with severe restrictive lung disease, reduced diffusing capacity, and exertional desaturation requiring oxygen supplementation. Previous treatments included topical therapies, acitretin, and intermittent systemic corticosteroids, which contributed to worsening skin disease. Bimekizumab was initiated after appropriate screening, resulting in rapid and complete skin clearance by week 12, with no adverse events. Over a 14-month follow-up, a progressive improvement in respiratory function was observed, including increased spirometric parameters, improved diffusing capacity, and enhanced exercise tolerance, with resolution of exertional desaturation and discontinuation of oxygen support…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.